LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

60.89 -0.64

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

60.84

Max

62.06

Pagrindiniai rodikliai

By Trading Economics

Pajamos

270M

124M

Pardavimai

320M

452M

Pelno marža

27.331

Darbuotojai

1,069

EBITDA

294M

150M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+12.19% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

3.2B

9.7B

Ankstesnė atidarymo kaina

61.53

Ankstesnė uždarymo kaina

60.89

Naujienos nuotaikos

By Acuity

13%

87%

16 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-17 23:01; UTC

Įsigijimai, susijungimai, perėmimai

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

2025-09-17 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

2025-09-17 21:59; UTC

Uždarbis

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

2025-09-17 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise as Yen Weakens -- Market Talk

2025-09-17 23:39; UTC

Rinkos pokalbiai

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

2025-09-17 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

2025-09-17 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

2025-09-17 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

2025-09-17 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

2025-09-17 22:18; UTC

Įsigijimai, susijungimai, perėmimai

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

2025-09-17 21:00; UTC

Uždarbis

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

2025-09-17 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-09-17 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-09-17 19:59; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-17 19:59; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

2025-09-17 19:07; UTC

Rinkos pokalbiai

Oil Futures Snap Three-Session Winning Streak -- Market Talk

2025-09-17 18:43; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

2025-09-17 18:38; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

2025-09-17 18:20; UTC

Rinkos pokalbiai

Gold Dips After Quarter-Point Rate Cut -- Market Talk

2025-09-17 18:18; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-17 18:18; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

2025-09-17 18:14; UTC

Rinkos pokalbiai

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

2025-09-17 17:59; UTC

Rinkos pokalbiai

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

2025-09-17 17:15; UTC

Įsigijimai, susijungimai, perėmimai

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

2025-09-17 17:06; UTC

Įsigijimai, susijungimai, perėmimai

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

2025-09-17 16:51; UTC

Uždarbis

Correct: Exor 1H Net Loss -EUR624M

2025-09-17 16:34; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-17 16:34; UTC

Rinkos pokalbiai

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

2025-09-17 16:25; UTC

Uždarbis

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

2025-09-17 16:23; UTC

Uždarbis

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

12.19% į viršų

12 mėnesių prognozė

Vidutinis 68.55 USD  12.19%

Aukščiausias 96 USD

Žemiausias 43 USD

Remiantis 21 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

21 ratings

16

Pirkti

4

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

16 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat